

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1430 Alexascins, Virginia 22313-1450 www.nepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/534,772	03/22/2007	Stephen Tomlinson	577712000200	1737
25226 77590 07/08/2010 MORRISON & FOERSTER LLP 755 PAGE MILL RD			EXAMINER	
			WEN, SHARON X	
PALO ALTO, CA 94304-1018			ART UNIT	PAPER NUMBER
			1644	
			MAIL DATE	DELIVERY MODE
			07/08/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

# Application No. Applicant(s) 10/534,772 TOMLINSON ET AL. Office Action Summary Examiner Art Unit SHARON WEN 1644 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 15 April 2009. 2a) ☐ This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4)\ Claim(s) 1.2.4-10.15-17.19.27-31.33.41.46-59 and 74-82 is/are pending in the application. 4a) Of the above claim(s) 5-7,15,16,19,27-31,33,41,46,47,53,55-59 and 74-82 is/are withdrawn from consideration. Claim(s) is/are allowed. 6) Claim(s) 1,2,4,8,17,48-52 and 54 is/are rejected. 7) Claim(s) 9 and 10 is/are objected to. 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some \* c) None of: Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). \* See the attached detailed Office action for a list of the certified copies not received.

1) Notice of References Cited (PTO-892)

2) Tildotice of Draftsperson's Patent Drawing Review (PTO-948)

Paper No(s)/Mail Date 05/23/2007, 12/03/2008, 4/15/2009 and 5/7/2010 .

Information Disclosure Statement(s) (PTO/SB/08)

Attachment(s)

Interview Summary (PTO-413)
 Paper No(e)Wall Date. \_\_\_\_\_.

6) Other:

5) Notice of Informal Patent Application

Art Unit: 1644

#### DETAILED ACTION

Applicant's amendment, filed 03/22/2007, has been entered.

Claims 3, 11-14, 18, 20-26, 32, 34-40, 42-45, 60-73 have been canceled.

Claims 1-2, 4-10, 15-17, 19, 27-31, 33, 41, 46-59 and 74-82 are pending.

### Election/Restrictions

Applicant's election without traverse of Group 4, drawn to a composition comprising CR2 and CD59, in the reply filed on 04/15/2009 is acknowledged.

Claims 5-7, 15-16, 19, 27-31, 33, 41, 46-47, 53, 55-59, 74-82 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected Inventions, there being no allowable generic or linking claim.

Claims 1-2, 4, 8-10, 17, 48-52, 54 are currently under examination as they read on a composition comprising a construct wherein the construct comprises a CR2 and CD59.

#### Information Disclosure Statement

The information disclosure statements (IDS) submitted on 05/23/2007, 12/03/2008, 4/15/2009 and 5/7/2010 have been considered by the examiner.

#### Claim Objections

Claim 1 is objected to because of the following informalities:

"SCR" and "CR2" should be spelled out the first time they appear in claims.

Appropriate correction is required.

## Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-2, 4, 48-51 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter

Art Unit: 1644

which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

There is insufficient written description of the genus encompassed by the recitation of "modulator of complement activity". It is noted that Applicant elected the CD59 antibody as the modulator; however the claims do not limit the modulator to CD59.

The specification discloses the modulator can be a CD59, Crry, DAF, CVF or an antibody. However, there is no information regarding what structural features would likely be associated with such selective, inhibitory activity because the specification does not describe the complete structure, partial structures, physical properties, or chemical properties of the modulator that selectively modulate the activity of complement as commensurate by the claims. Thus, the specification does not disclose a correlation between selective modulatory activity and structure of a putative inhibitory compound.

The level of the skill and knowledge in the art is such that there is no known correlation between any structural component and the ability to selectively inhibit complement for the genus of inhibitory compounds encompassed by the claims. Thus, the disclosure does not allow one of skill in the art to visualize or recognize the structure of any compound required to practice the claimed invention. Accordingly, one of skill in the art would conclude that Applicant would not have been in possession of the claimed composition comprising the compounds because the genus of modulator possessing the desired activity are not adequately described in the instant disclosure as-filed.

Applicant is invited to amend the claim to recite the elected invention, i.e., CD59 as the modulator to obviate this rejection.

## Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where

Art Unit: 1644

the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1988); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Omum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1989))

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1, 2, 4, 8, 17, 48-52 and 54 are *provisionally* rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-4 of copending Application No. 11/997,650. Although the conflicting claims are not identical, they are not patentably distinct from each other for the following because both sets of the claims are drawn to a fusion construct comprising CR2 and CD59. Therefore, they would have anticipated or rendered obvious of one another.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

# Allowable Subject Matter

Claims 9-10 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

### Conclusion

No claim is allowed.

Art Unit: 1644

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHARON WEN whose telephone number is (571)270-3064. The examiner can normally be reached on Monday-Thursday, 8:30AM-6:00PM, ALT. Friday, EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on (571)272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Sharon Wen/ Examiner, Art Unit 1644 July 1, 2010